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a b s t r a c t
The Major Immediate Early Promoter (MIEP) of human cytomegalovirus (HCMV) controls viral
Immediate Early (IE) gene expression, which must be activated to initiate productive infection and
repressed to establish latency. Regulation of the MIEP is critical for both viral spread and persistence.
In addition to the Daxx-mediated intrinsic cellular defense that regulates the MIEP, the cell-type speciﬁc
balance between cellular activators and repressors of the promoter may help dictate whether viral IE
genes will be expressed or silenced. For example, in undifferentiated myeloid cells, transcriptional
repressors of the MIEP may outnumber transcriptional activators, leading to promoter silencing and
latency establishment. We created a recombinant viral genome in which a myeloid-active promoter
replaced part of the MIEP. The viable virus generated failed to express the viral IE genes in an
undifferentiated myeloid cell line. These observations have mechanistic implications regarding how
viral IE gene expression is regulated during latency.
& 2013 Elsevier Inc. All rights reserved.
Introduction
The human cytomegalovirus (HCMV) causes disease by pro-
ductively replicating in epithelial, endothelial, smooth muscle,
ﬁbroblast, placental trophoblast, and differentiated myeloid line-
age cells, such as macrophage and dendritic cells (Sinzger et al.,
2008). It persists for the life of the infected host by establishing
latent infections in undifferentiated cells of the myeloid lineage
(Goodrum et al., 2012). Thus, HCMV must be equipped to express
its lytic phase genes in multiple cell types, silence them to
establish and maintain latent reservoirs, and activate (animate)
them to reactivate from latency to productive replication (Penkert
and Kalejta, 2011). Much of the lytic phase transcriptional program
is initiated by the viral Immediate Early (IE) 1 and IE2 proteins,
encoded within the viral genome's Unique Long (UL) region by the
UL123 and UL122 genes (respectively). They are among the ﬁrst
genes to be expressed upon initiation of a lytic infection, but are
not expressed during latency. Expression (or repression) of IE1 and
IE2 is controlled by the Major Immediate Early Promoter (MIEP)
(Meier and Stinski, 2006).
The MIEP consists of a core promoter (P) (nucleotide positions þ1
(the transcription start site) to 39), an enhancer (E) divided into
proximal (39 to 300) and distal (300 to 550) components, a
unique region (U) (500 to 750) and a modulator (M) (750 to
1140) (Fig. 1). Truncated versions of the MIEP containing the
promoter, proximal enhancer, and sometimes the distal enhancer are
ubiquitously present in expression vectors for use in mammalian cells,
where they are often referred to as simply “the CMV promoter”.
A substantial number of transcription factor binding sites have been
identiﬁed by both bioinformatic and experimental approaches, and
presumably these sites contribute to both the wide array of cell types
in which the promoter is active, as well as the comparative strength of
the promoter within those cells. Despite the awesome power of this
promoter, it has also evolved to sustain transcriptional repression
during latency.
At least three mechanisms conspire to silence the MIEP during
latency. These are a cellular intrinsic immune defense found in all
cells tested to date (Saffert and Kalejta, 2006, 2007; Saffert et al.,
2010), an unidentiﬁed viral function (or functions) encoded only
by certain strains of the virus (Saffert et al., 2010), and the
potential activity of the promoter, likely controlled by the balance
between positive and negative cellular regulators of the MIEP
expressed in a cell type-speciﬁc manner (Reeves, 2011; Saffert
et al., 2010; Sinclair, 2010). The cellular Daxx intrinsic immune
protein silences viral gene expression by instituting a repressive
chromatin structure at the MIEP (Tavalai and Stamminger, 2011;
Woodhall et al., 2006). It is inactivated in cells destined to initiate a
lytic infection when the tegument-delivered pp71 protein trafﬁcs
to the nucleus and degrades Daxx, but remains active during the
establishment of latency because tegument-delivered pp71
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localizes to the cytoplasm in these cells (Penkert and Kalejta,
2012). Artiﬁcial inactivation of the Daxx defense with histone
deacetylase (HDAC) inhibitors is sufﬁcient to activate the MIEP and
drive IE gene expression in cells where the virus would otherwise
establish latency, but only when the laboratory adapted AD169
virus strain is used for infections (Albright and Kalejta, 2013;
Penkert and Kalejta, 2013; Qin et al., 2013; Saffert and Kalejta,
2007). IE gene expression from clinical virus strains that encode
additional genes in the ULb' genomic locus is not rescued by HDAC
inhibition, indicating that these viral strains impose an additional
impediment to viral IE gene expression during latency above and
beyond that instituted by Daxx (Saffert et al., 2010). Finally, in the
context of a recombinant adenoviral genome, a truncated MIEP is
10–1000-fold less active in undifferentiated cell types where the
virus establishes latency as compared to differentiated cell types
where it initiates a lytic infection (Saffert et al., 2010). This ﬁnding
seems to support the long-held contention (Reeves, 2011; Sinclair,
2010) that the balance between cellular MIEP activating and
repressing factors is tipped in favor of repression in cell types
where the virus establishes latency.
In attempts to alter this balance, we generated recombinant
HCMVs in which all or part of the MIEP was replaced with the
Long Terminal Repeat (LTR) of the Spleen Focus Forming Virus
(SFFV), a promoter known to be active in undifferentiated cells of
the myeloid lineage (Baum et al., 1995; Carter et al., 2010; Gutsch
et al., 2011). Furthermore, we employed the AD169 strain to avoid
the complication of the additional clinical strain-speciﬁc restric-
tion. Recombinants in which the SFFV promoter replaced the
entire MIEP, or the proximal and distal enhancers, were not viable.
A recombinant in which the SFFV promoter replaced part of the
unique region and the modulator grew with wild type kinetics in
fully differentiated ﬁbroblasts, but failed to express viral IE genes
in THP-1 monocytes, incompletely differentiated myeloid cells that
are used to study viral transcriptional silencing during experi-
mental latency. As our recombinant viruses apparently failed to
shift the equilibrium between positive and negative MIEP regula-
tors enough to overcome the intrinsic defense and perhaps other
cellular responses to foreign DNAs, the promoter elements that
control HCMV IE gene repression during latency remain enigmatic,
while appreciation for the controlling contribution of intrinsic
cellular silencing mechanisms is reinforced.
Results
The SFFV promoter cannot replace the MIEP
HCMV recombinants in which mutant MIEPs with deleted
segments drive substantially lower expression levels of IE tran-
scripts display moderate to severe growth defects, but nonetheless
are viable (Isomura et al., 2004; Meier and Pruessner, 2000; Meier
and Stinski, 1997; Stinski and Isomura, 2008). Therefore we
reasoned that replacing all or part of the MIEP with the SFFV
promoter may result in a virus crippled yet competent for
productive replication in differentiated ﬁbroblasts, and because
the hybrid promoter now driving IE1 and IE2 expression contains
elements geared for activation in myeloid lineage cells (Baum
et al., 1995; Carter et al., 2010; Gutsch et al., 2011), this recombi-
nant may fail to silence IE genes and thus fail to establish latency
upon infection of incompletely differentiated myeloid cells. Infect-
ing THP-1 cells with a virus harboring a hybrid SFFV-MIEP and
comparing the propensity for IE gene expression to wild type virus
tests the hypothesis that the balance between binding sites for
positive and negative regulators within the promoter has a
dominant controlling effect on viral IE gene expression during
the establishment of latency. However, recombinant viruses
rendered competent for IE gene expression in such a manner are
still not expected to productively replicate, as it has been clearly
shown that forcing IE gene expression in undifferentiated cells
does not result in productive replication (Saffert and Kalejta, 2007;
Yee et al., 2007). Such an abortive infection would likely prove
immunogenic, providing an additional reason (other than the
seeding of the latent reservoir) for HCMV IE gene expression to
be silenced upon infection of undifferentiated myeloid cells.
Replacing the entire MIEP with the SFFV promoter (BAD-SF;
Fig. 1) resulted in a recombinant genome (Fig. 2A,B) that failed to
generate infectious progeny virions upon transfection with a
pp71-expressing plasmid into fully permissive human ﬁbroblasts,
judged by the inability to observe a spreading plaque by GFP
ﬂuorescence (Fig. 2C). This was somewhat surprising as the SFFV
promoter and the MIEP showed statistically indistinguishable
activity in a reporter assay in the same population of ﬁbroblasts
(Fig. 2D), reinforcing the notion that promoters are regulated
differently within infecting viral genomes and transfected plas-
mids. Replacing the SFFV promoter in BAD-SF with the MIEP (BAD-
Rev; Fig. 1) generated an infectious, revertant genome (Fig. 2A–C)
indicating that the lesion at the MIEP was responsible for the
growth defect of BAD-SF.
Supplementing the SFFV sequences in BAD-SF by replacing
most of the core promoter without (BAD-P) or with (BAD-554) the
unique region and the modulator (Fig. 1) also generated viral
genomes (Fig. 2A and B) that were not converted to expanding
plaques or infectious virus upon transfection with a pp71-
expressing plasmid into ﬁbroblasts (Fig. 2C). Inserting the unique
region and the modulator, elements known to contain binding
sites for repressive transcription factors including Yin-Yang-1
(YY1), ETS2-repressor factor (ERF) and Silencing Binding Protein
(SBP) (Bain et al., 2003; Huang et al., 1996; Liu et al., 1994) actually
impaired the activity of the hybrid promoter in a reporter assay
(Fig. 2D). Inserting the MIEP core promoter, proximal and distal
enhancers, and part of the unique region in between the SFFV
promoter and the transcription start site (BAD-662; Fig. 1) gener-
ated an infectious, recombinant genome (Fig. 2A–C) and a hybrid
promoter with increased activity in reporter assays compared to
the full length MIEP (Fig. 2D), and similar activity to a promoter
containing only the extant MIEP sequences (Fig. 2E).
Fig. 1. Promoter region of the major immediate early locus of wild type HCMV and
SFFV-LTR recombinants. Functional regions of the MIEP are numbered relative to
the transcription start site (þ1). These include the core promoter (P), the enhancer (E),
which is divided into proximal and distal components, the unique region (U), and the
modulator (M). Recombinants are given full names based on the location of the
insertion (MIEP) and the inserted sequences (P, E, U, and M). Abbreviated names are
used for simplicity. BAD-SF represents a complete deletion of the MIEP with insertion
of the SFFV LTR. BAD-P retains a portion of the core promoter with insertion of the
SFFV LTR. BAD-554 retains the modulator and unique regions with an insertion of the
SFFV LTR. BAD-662 retains the core promoter, proximal and distal enhancers, and a
portion of the unique region with an insertion of the SFFV LTR. BAD-Rev represents a
revertant of BAD-SF to the wild type sequence. See Materials and methods for details.
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Interestingly, transfected recombinant genomes (BAD-SF, BAD-P,
and BAD-552) for non-infectious viruses resulted in the expression
of IE1 and IE2, and the early protein UL44 (Fig. 3). Qualitative
examination suggested a similar percentage of cells in each trans-
fection went on to express IE and UL44 proteins. However, no viral
DNA replication was observed. All viral genomes were detectable as
transfected BAC clones by PCR in total DNA prepared from cells one
day after transfection (Fig. 4). Prior digestion with DpnI (which
digests methylated, bacterially-produced DNAs, but not hemi- or
unmethylated DNA produced in mammalian cells) (Lacks and
Greenberg, 1977) prevented their detection. By thirteen days after
transfection, wild type and BAD-662 viral genomes had replicated,
as they were detectable in both DpnI-treated and untreated DNA
preparations. Other recombinant viral genomes were undetectable
even in the absence of DpnI digestion, likely indicating that the
transfected genomes, in the absence of replicative ampliﬁcation,
were degraded. Not surprisingly, recombinants unable to replicate
their DNA (BAD-SF, BAD-P, and BAD-554) also failed to express the
late UL99 gene that encodes the pp28 protein (Fig. 3), and never
showed any signs of generating spreading plaques, although single
IE1-positive cells could still be detected as long as 58 days after
transfection in one experiment (data not shown). Thus, non-viable
recombinants inwhich the SFFV promoter replaced all or part of the
MIEP were competent for the expression of the major IE genes and
at least one early gene, but failed to replicate their DNA or express
late genes.
Virus with a chimeric MIEP/SSFV promoter (BAD-662) replicates
with wild type kinetics in ﬁbroblasts
The only viral genome we created with a chimeric MIEP/SFFV
promoter driving expression of the MIE locus that generated a
spreading plaque contained the entire SFFV promoter and the
promoter, enhancer and unique region of the MIEP (BAD-662,
Fig. 1). This virus was recoverable, and stocks were prepared. The
kinetics of viral IE, E, and L protein expression between BAD-662
and wild type virus were indistinguishable (Fig. 5A). Likewise,
progeny virion production between the two viruses was essen-
tially identical at both high (Fig. 5B) and low (Fig. 5C) multiplicities
of infection. Therefore we conclude that BAD-662 productively
infects and replicates in ﬁbroblasts as well as wild type virus.
Viral IE gene expression from BAD-662 is silenced upon infection
of THP-1 cells
Our ability to produce BAD-662 virus allowed us to test
whether inserting myeloid active promoter elements into the
MIEP could disrupt the balance between factors that promote or
repress transcription, and thus drive viral IE gene expression in
undifferentiated myeloid cells where they are normally silenced.
Viral IE RNA accumulation was inhibited upon infection of THP-1
monocytes with both wild type and BAD-662 (Fig. 6). The HDAC
inhibitor VPA promoted viral gene expression from both viruses,
indicating not only that viral genomes successfully entered the
nucleus, but also that they were efﬁciently silenced by the cellular
intrinsic defense. Similar results were obtained when viral IE1
protein accumulation was monitored (Fig. 7). Interestingly, this
hybrid promoter showed similar activity in a reporter assays in
THP-1 cells when compared to either the full length (Fig. 8A) or a
truncated (Fig. 8B) MIEP. This further conﬁrms the inability of
reporter assays to accurately reﬂect promoter activity within
HCMV genomes. The combined removal of binding sites for
repressive factors and the insertion of myeloid active promoter
elements were insufﬁcient to drive viral IE gene expression in
Fig. 2. Recombinant genomes differ in abilities to reconstitute infectious virus. A. Recombinant BACs were digested with Bbv CI, bands were separated by agarose gel
electrophoresis and stained with ethidium bromide. M, size markers. B. The MIEP region of each recombinant was ampliﬁed by PCR, products were separated by agarose gel
electrophoresis and stained with ethidium bromide. M, size markers. C. Recombinant genomes were transfected into fully permissive human ﬁbroblasts. Thirty days after
transfection, representative images were captured by ﬂuorescence microscopy. D. HFs were transfected with ﬁreﬂy luciferase reporter plasmids driven by the indicated
promoter. Fireﬂy luciferase activity relative to a co-transfected Renilla luciferase reporter is displayed with standard deviation. WT and SF were not statistically different
(p¼0.91). P (po0.01), 554 (po0.01) and 662 (po0.05) were statistically different than WT. E. Luciferase assay as in panel D with the indicated promoters (p¼0.84).
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incompletely differentiated myeloid lineage cells. This could indi-
cate that intrinsic, perhaps catholic repressive mechanisms play a
dominant role to speciﬁc activating promoter elements when
HCMV gene expression is silenced during the establishment of
experimental latency, and that sequences in the unique region or
the modulator are not required for the suppression of MIEP
activity observed in these cells. The latter speculation is conﬁrmed
by the observation that an HCMV mutant lacking the unique
region and the modulator is silenced upon infection of THP-1 cells
(Fig. 8C).
Discussion
Substantial efforts to understand how the overall structure of,
or individual elements within the HCMV MIEP, modulates its
activity have failed to produce a clear picture of how this sequence
either activates or represses transcription. Early approaches with
reporter assays mapped regions and transcription factor binding
sites that, when deleted or mutated, altered promoter functions.
However, these lesions, in general, fail to produce the same effects
when incorporated into recombinant viral genomes and tested
under more physiologic assay conditions (Stinski and Isomura,
2008). We obtained similar results here, where the SFFV-modiﬁed
promoters showed similar (Fig. 2E) or enhanced (Fig. 2D) activity
compared to the MIEP in reporter assays but failed to support virus
propagation (Fig. 2C), and while active in reporter constructs
(Fig. 8) were silenced in the viral genome (Fig. 6) in THP-1 cells.
Thus, the only appropriate test for physiologically relevant pro-
moter function is in the context of a recombinant virus.
Therefore, we addressed the question of how the balance
between sites for positively- and negatively-acting transcription
factors modulates MIEP repression during the establishment of
experimental HCMV latency by testing chimeric promoters in the
context of the viral genome during infection of THP-1 cells. The
recombinant virus we created (BAD-662) harbors a hybrid MIEP
retaining native features critical for promoter activity (Isomura
et al., 2005, 2008, 2004) but missing numerous binding sites for
transcriptional repressors (Bain et al., 2003; Huang et al., 1996;
Liu et al., 1994). Furthermore, binding sites for positively acting
transcriptional activators in hematopoietic cells (SP1, ETS, GATA,
CBF, E-box, etc.) have been inserted in the form of the SFFV
promoter (Baum et al., 1997; Wahlers et al., 2002; Zychlinski
et al., 2008). Despite this substantial change in the balance
between sequences able to bind transcriptional activators or
repressors, this hybrid promoter in the context of the HCMV
genome was still repressed upon infection of THP-1 cells and the
establishment of experimental latency.
Neither inserting complete, heterologous viral promoters at
different locations within the HCMV genome (Qin et al., 2013), nor
altering the balance between the binding sites for activating and
repressing transcription factors at the MIEP, at least in the
proportion we have here, is sufﬁcient to avoid transcriptional
silencing during the establishment of latency. Such silencing
occurs in part through a cellular intrinsic defense mediated by
Daxx and HDACs (Saffert and Kalejta, 2007; Saffert et al., 2010),
Fig. 3. Non-viable recombinants express representative immediate early and early, but not late genes. Fibroblasts were transfected with the indicated recombinant genomes
and a pp71-expression plasmid and thirteen days later, cells grown on coverslips were stained for the indicated viral antigen (red) and visualized by indirect
immunoﬂuorescence microscopy. Nuclei were stained with DAPI (blue) and are displayed in merged images to the left of each viral antigen. Representative images
are shown.
Fig. 4. Non-viable recombinants fail to replicate viral DNA. Total DNAwas extracted
either one or thirteen days post transfection (dpt) of ﬁbroblasts with the indicated
recombinant BAC genomes. Aliquots were digested (þ) or not () with DpnI. The
MIEP region was ampliﬁed by PCR, products were separated by agarose gel
electrophoresis and stained with ethidium bromide. M, size markers.
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and here we have conﬁrmed HDACs contribute to repression of the
SFFV-hybrid MIEP during the establishment of experimental
latency in THP-1 cells. We therefore hypothesize that initial
silencing during the establishment of latency occurs through a
broad, likely promoter element-independent mechanism insti-
tuted by cellular intrinsic immune factors and sensors of foreign
DNA. While speciﬁc promoter elements may help perpetuate
repression of the MIEP during latency, they do not appear to play
dominant roles during latency establishment. Identifying compo-
nents of intrinsic, restrictive defenses that transcriptionally silence
infecting viral genomes (in addition to Daxx and HDACs) will be
required before more detailed mechanisms can be delineated.
Interestingly, all of our non-viable recombinant genomes were
capable of expressing IE1 and IE2 when transfected into fully
permissive ﬁbroblasts (Fig. 3). Though quantitative comparisons of
such experiments are difﬁcult, we speculate that the level of IE
gene expression was reduced compared to wild type. However,
sufﬁcient levels of IE proteins were generated to activate the
expression of at least one early gene, UL44 (Fig. 3). Thus these
recombinant genomes, though non-viable, were able to progress
past the IE stage and into the early stage of HCMV infection. Why
the gene expression achieved with these non-viable recombinants
was sufﬁcient to progress into, but not complete the early stage of
infection (Fig. 4) is unclear. Recently, it was demonstrated that the
rate of IE protein accumulation, independent of absolute levels,
provides a replication advantage for HCMV (Teng et al., 2012).
Accelerated accumulation of IE1 and IE2 likely establishes replica-
tion competence prior to the activation of innate immunity, while
maintaining reasonably low levels of these proteins likely miti-
gates their toxicity. Thus, perhaps the SFFV sequences in our
mutant viruses can produce the required amounts of IE proteins
to activate early gene expression, but cannot produce them fast
enough to allow the early phase of the viral life cycle sufﬁcient
time to establish itself prior to inhibition by cellular innate
immune proteins. Thus, while speciﬁc promoter elements appear
to be unimportant for silencing during the establishment of
latency, they seem to be critical for orchestrating the precise
pattern of IE gene expression required for de novo lytic infection,
and perhaps the animation of viral gene expression that occurs
during reactivation from latency.
Materials and methods
Cells and viruses
Human foreskin ﬁbroblasts (HFs) were cultured in Dulbecco's
modiﬁed Eagle's medium (DMEM) (Invitrogen) supplemented
with 10% (vol/vol) fetal bovine serum (Gemini), 100 U/ml penicil-
lin, and 100 μg/ml streptomycin plus 0.292 mg/ml glutamine
(Gibco), in a 5% CO2 atmosphere at 37 1C. THP-1 cells were
cultured in RPMI 1640 medium (Invitrogen) supplemented as
above. Wild type and recombinant HCMVs were rescued from
the AD169 BAC (Terhune et al., 2007) and tittered by plaque assay.
Recombinant HCMV lacking the unique region and modulator
(582/1108) was previously described (Meier and Pruessner,
2000).
Viral reverse genetics
HCMV BACs were mutagenized as previously described (Tischer
et al., 2010). The MIEP (1140 to 1, relative to transcription start
site þ1) was replaced with the SFFV LTR (from pSR-CMV-MLV-
SIN) (Wu and Lu, 2010) to make BAD-MIEP/SF. A revertant (BAD-
MIEP/SF-Rev) was made from BAD-MIEP/SF by replacing SFFV
sequences with the MIEP. The MIEP (1140 to 30) was replaced
Fig. 5. BAD-662 displays gene expression and viral replication kinetics indistin-
guishable from wild type virus. A. Lysates prepared at the indicated hour post
infection from ﬁbroblasts infected at a multiplicity of infection (MOI) of 1 with the
indicated virus were analyzed by Western blotting with the indicated antibodies.
Actin serves as a loading control. M, mock infection. B. Samples were prepared at
the indicated day post infection (dpi) from supernatants and attached cells infected
at an MOI of 1 with the indicated virus and tittered by plaque assay. Error bars
represent standard deviations. C. Growth curves as described in panel B were
conducted after infections at an MOI of 0.1.
Fig. 6. Transcription of the major immediate early locus of BAD-662 in THP-1 cells
requires HDAC inhibition. THP-1 cells pretreated (þ) or not () with VPA for 3 h
were infected with the indicated virus at an MOI of 2. Total RNA was extracted 20 h
later and analyzed for the expression of the indicated viral (IE1) or cellular (GAPDH)
gene by RT-PCR. Products were separated by agarose gel electrophoresis and
stained with ethidium bromide. M, mock infection.
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with SFFV to make BAD-MIEP/SFþP. The MIEP (1140 to 554)
was added back to BAD-MIEP/SF to make BAD-MIEP/SFþMU. The
MIEP (662 to 1) was added back to BAD-MIEP/SF to make
BAD-MIEP/SFþUEP. See Fig. 1 for schematic representation and
nomenclature abbreviations. All primers used for making BACs are
listed in Table 1. BACs were conﬁrmed by restriction digest and
sequencing. To reconstitute virus, HFs were transfected with 20 ug
of BACs and 5 ug of plasmid pCGN-pp71 in 350 ul Ingenio
Electroporation solution (Mirus) in 4 mm Cuvette at 260 V,
950 uF (Bio-Rad, GenePulser X cell™) and cultured up to 30 days.
Indirect immunoﬂuorescence
Transfected HFs were grown on coverslips. Infected, suspension
THP-1 cells were collected by low-speed centrifugation, treated
with trypsin (0.5 mg/ml) for 5 min at 37 1C, collected again by low-
speed centrifugation, resuspended in cold phosphate-buffered
saline (PBS), and allowed to attach to water-washed coverslips
for 60 min at room temperature. Cells on coverslips were ﬁxed
with 2% paraformaldehyde in PBS. After washing with PBST (PBS
plus 0.1% Triton X-100 and 0.05% Tween 20) coverslips were
Fig. 7. Viral IE protein expression from BAD-662 in THP-1 cells requires HDAC inhibition. THP-1 cells pretreated with VPAwhere indicated (þVPA) for 3 h were infected with
the indicated virus at an MOI of 2 and, 20 h later were attached to coverslips, stained for the viral IE1 protein (red) and visualized by indirect immunoﬂuorescence
microscopy. Nuclei stained with DAPI (blue) are displayed alone and in merged images.
Fig. 8. Wild type and SFFV-hybrid MIEPs are active on transfected plasmids in THP-1 cells. A. THP-1 cells were transfected with ﬁreﬂy luciferase reporter plasmids driven by
the indicated promoter. Fireﬂy luciferase activity relative to a co-transfected Renilla luciferase reporter is displayed with standard deviation. WT and BAD662 were not
statistically different (p¼0.63). B. Luciferase assay as in panel A with the indicated promoters (p¼0.003). C. THP-1 cells pretreated (þ) or not () with VPA for 3 h were
infected with the indicated virus at an MOI of 2. Total RNA was extracted 20 h later and analyzed for the expression of the indicated viral (IE1) or cellular (GAPDH) gene by
RT-PCR. Products were separated by agarose gel electrophoresis and stained with ethidium bromide. M, mock infection.
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blocked with PBST plus 5% goat serum and 0.5% bovine serum
albumin for 30 min. Cells were then incubated for 1 h with
primary antibodies speciﬁc for IE1 (1B12), IE2 (3H9), UL44
(CA006-100; Virusys), or pp28 (CMV157), washed three times
with PBST, and then incubated for an additional hour with
secondary antibodies. Immunostained cells were washed a ﬁnal
three times with PBS, and mounted on slides with ProLongs
reagent with DAPI (4′, 6-diamidino-2-phenylindole dihydrochlor-
ide) (Invitrogen). Images were captured with a Zeiss microscope
and camera (Axiovert 200M).
Western blotting
Cells were lysed in radioimmunoprecipitation assay (RIPA)
buffer as described previously (Saffert and Kalejta, 2006). Equal
amounts of protein were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and immobilized
on Optitran nitrocellulose membranes. The membrane was
blocked for 15 min with 5% non-fat skim milk in Tris-buffered
saline (20 mM Tris, 137 mM NaCl [pH 7.6]) containing 0.1% Tween-
20 (TBS-T) and then incubated for 4 h with primary antibodies (see
above) in TBS-T containing 1% milk. Blots were washed three times
for 15 min each with TBS-T, followed by a 4 h incubation with
HRP-conjugated secondary antibodies in TBS-T containing 1% milk.
Blots were washed three times and developed with the ECL
enhanced chemiluminescence system (Thermo Scientiﬁc).
PCR and RT-PCR
To monitor viral DNA replication, total DNA was extracted by
mini DNA extraction kit (Qiagen) one or thirteen days after BAC
transfection. Aliquots were digested with Dpn I, the MIEP regions
was ampliﬁed by PCR with the primers indicated in Table 1, and
products were separated by ethidium bromide agarose gel elec-
trophorsesis. To analyze the transcription of IE gene in undiffer-
entiated cells, THP-1 cells (1106) were pretreated with or
without VPA (100 ug/ml) and then infected with wild type
AD169 or BAD-662 at an MOI of 2. Total RNA was extracted with
the RNeasy minikit (Qiagen) at 20 hpi. Isolated RNA was quanti-
ﬁed, and equivalent amount (2 ug) of each sample was treated
with RNase-free DNase (Promega) following the manufacturer's
protocol. Equivalent amount (0.1 ug) of RNA was subsequently
used in a reverse transcription (RT) as described in the manual of
SuperScript III First Strand Synthesis kit (Invitrogen). cDNA was
used for PCR with Taq ﬂexi polymerase (Promega). All primers
used are listed in Table 1.
Luciferase assays
A dual luciferase reporter assay system (Promega) was employed.
Wild type and SFFV-hybrid MIEPs were ampliﬁed by PCR from BAC
genomes and inserted into pGL-3. THP-1 cells (1106) were
transfected with Lipofectamine 2000 (Invitrogen) in Opti-MEM-1
(Invitrogen) with 200 ng of pGL-3 based Fireﬂy reporters and 400 ng
pRL-TK-Renilla as a normalization control. HFs (3.5105) were
transfected as above. Media was changed at 24 h and lysates were
harvested at 48 h in 40 ul of Passive Lysis Buffer (Promega).
Luciferase activities were quantitated with a Veritas microplate
luminometer (Turner Biosystems) and are expressed as Fireﬂy
relative to Renilla. Values were compared with Student’s T test.
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